Loading...
Loading...
CRIS| Name | Value |
|---|---|
| Revenues | 2.9M |
| Cost of Revenue | 0.0M |
| Gross Profit | 2.9M |
| Operating Expense | 13.5M |
| Operating I/L | -10.6M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.3M |
| Pretax | -10.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -10.1M |
Curis, Inc. is a biotechnology company focused on discovering and developing drug candidates for the treatment of human cancers. Their clinical stage drug candidates include Emavusertib, CI-8993, Fimepinostat, CA-170, and CA-327, targeting various types of cancers such as non-hodgkin lymphomas, acute myeloid leukemia, myelodysplastic syndromes, and diffuse large B-cell lymphoma. The company also has collaboration agreements with F. Hoffmann-La Roche Ltd., Genentech Inc., and Aurigene Discovery Technologies Limited for the development and commercialization of oncology drugs and small molecule compounds in the areas of immuno-oncology and precision oncology.
